Effector Therapeutics Stock Shares Owned By Insiders
| EFTR Stock | USD 2.20 0.04 1.85% |
Effector Therapeutics fundamentals help investors to digest information that contributes to Effector Therapeutics' financial success or failures. It also enables traders to predict the movement of Effector Stock. The fundamental analysis module provides a way to measure Effector Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Effector Therapeutics stock.
Effector | Shares Owned By Insiders |
Effector Therapeutics Company Shares Owned By Insiders Analysis
Effector Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Effector Therapeutics Shares Owned By Insiders | 2.84 % |
Most of Effector Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Effector Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Effector Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Effector Therapeutics is extremely important. It helps to project a fair market value of Effector Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Effector Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Effector Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Effector Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 2.84% of Effector Therapeutics are shares owned by insiders. This is 81.29% lower than that of the Biotechnology sector and 79.97% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 71.85% higher than that of the company.
Effector Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Effector Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Effector Therapeutics could also be used in its relative valuation, which is a method of valuing Effector Therapeutics by comparing valuation metrics of similar companies.Effector Therapeutics is currently under evaluation in shares owned by insiders category among related companies.
Effector Fundamentals
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.85 | ||||
| Current Valuation | 10.29 M | ||||
| Shares Outstanding | 4.7 M | ||||
| Shares Owned By Insiders | 2.84 % | ||||
| Shares Owned By Institutions | 14.03 % | ||||
| Number Of Shares Shorted | 244.03 K | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 13.38 X | ||||
| Price To Sales | 69.65 X | ||||
| Gross Profit | (19.76 M) | ||||
| EBITDA | (33.73 M) | ||||
| Net Income | (35.81 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 19.45 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | (1.94) X | ||||
| Cash Flow From Operations | (29.55 M) | ||||
| Short Ratio | 0.30 X | ||||
| Earnings Per Share | (16.37) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 10.35 M | ||||
| Total Asset | 20.54 M | ||||
| Retained Earnings | (179.38 M) | ||||
| Working Capital | (5.96 M) | ||||
| Net Asset | 20.54 M |
About Effector Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Effector Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Effector Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Effector Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Effector Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Effector Therapeutics' short interest history, or implied volatility extrapolated from Effector Therapeutics options trading.
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Effector Stock
| 0.68 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Effector Stock
| 0.57 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
| 0.43 | ELVN | Enliven Therapeutics Trending | PairCorr |
| 0.41 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Effector Therapeutics Piotroski F Score and Effector Therapeutics Altman Z Score analysis. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Effector Stock analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.37) | Revenue Per Share 0.349 | Quarterly Revenue Growth 1.17 | Return On Assets (0.85) | Return On Equity (9.47) |
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.